Homma Y, Ohshima K, Yamaguchi H, Nakamura H, Araki G, Goto Y
Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Atherosclerosis. 1991 Nov;91(1-2):145-53. doi: 10.1016/0021-9150(91)90196-a.
The effects of 12 weeks eicosapentaenoic acid (EPA) administration (2.7 g/day) on plasma lipoprotein subfraction levels and on activities of lecithin: cholesterol acyltransferase (LCAT) and lipid transfer protein (LTP) were investigated. Plasma VLDL-C, VLDL-TG, VLDL-PL, VLDL-apo B, VLDL-apo C-II and VLDL-apo C-III levels were decreased by 32.8% (P less than 0.05), 31.2% (P less than 0.01), 31.5% (P less than 0.05), 32.5% (P less than 0.05), 34.7% (P less than 0.05) and 34.1% (P less than 0.05), respectively. EPA did not change plasma IDL-TC, IDL-TG, IDL-PL and IDL-apo B levels. Plasma large, light LDL (LDL1)-TC, LDL1-PL and LDL1-apo B levels were decreased by EPA by 18.7% (P less than 0.02), 19.1% (P less than 0.01) and 23.3% (P less than 0.01) while LDL1-TG level was not changed. Plasma small, heavy LDL (LDL2)-TC level was increased by 25.7% (P less than 0.02) while LDL2-TG, LDL2-PL and LDL2-apo B levels were not altered. Plasma HDL2-TC, HDL2-TG, HDL2-PL and HDL2-apo A-I levels stayed unchanged by EPA treatment. EPA did not affect plasma HDL3-TC, HDL3-PL and HDL3-apo A-I levels but decreased HDL3-TG level significantly (P less than 0.02). LCAT activity was not altered by EPA. LTP activity was increased by 24.8% at 4 weeks (P less than 0.02) and by 32.1% (P less than 0.001) at 12 weeks EPA treatment. We conclude that EPA reduces plasma large, light LDL levels as well as plasma VLDL amounts and stimulates LTP activities.
研究了12周二十碳五烯酸（EPA）给药（2.7克/天）对血浆脂蛋白亚组分水平以及卵磷脂胆固醇酰基转移酶（LCAT）和脂质转运蛋白（LTP）活性的影响。血浆极低密度脂蛋白胆固醇（VLDL-C）、极低密度脂蛋白甘油三酯（VLDL-TG）、极低密度脂蛋白磷脂（VLDL-PL）、极低密度脂蛋白载脂蛋白B（VLDL-apo B）、极低密度脂蛋白载脂蛋白C-II（VLDL-apo C-II）和极低密度脂蛋白载脂蛋白C-III（VLDL-apo C-III）水平分别降低了32.8%（P<0.05）、31.2%（P<0.01）、31.5%（P<0.05）、32.5%（P<0.05）、34.7%（P<0.05）和34.1%（P<0.05）。EPA未改变血浆中间密度脂蛋白胆固醇（IDL-TC）、中间密度脂蛋白甘油三酯（IDL-TG）、中间密度脂蛋白磷脂（IDL-PL）和中间密度脂蛋白载脂蛋白B（IDL-apo B）水平。EPA使血浆大的、轻的低密度脂蛋白（LDL1）胆固醇（LDL1-TC）、LDL1磷脂（LDL1-PL）和LDL1载脂蛋白B（LDL1-apo B）水平分别降低了18.7%（P<0.02）、19.1%（P<0.01）和23.3%（P<0.01），而LDL1甘油三酯水平未改变。血浆小的、重的低密度脂蛋白（LDL2）胆固醇（LDL2-TC）水平升高了25.7%（P<0.02），而LDL2甘油三酯、LDL2磷脂和LDL2载脂蛋白B水平未改变。EPA治疗后，血浆高密度脂蛋白2胆固醇（HDL2-TC）、HDL2甘油三酯（HDL2-TG）、HDL2磷脂（HDL2-PL）和HDL2载脂蛋白A-I（HDL2-apo A-I）水平保持不变。EPA不影响血浆高密度脂蛋白3胆固醇（HDL3-TC）、HDL3磷脂（HDL3-PL）和HDL3载脂蛋白A-I（HDL3-apo A-I）水平，但显著降低了HDL3甘油三酯水平（P<0.02）。EPA未改变LCAT活性。EPA治疗4周时LTP活性增加了24.8%（P<0.02），12周时增加了32.1%（P<0.001）。我们得出结论，EPA可降低血浆中大的、轻的低密度脂蛋白水平以及血浆极低密度脂蛋白量，并刺激LTP活性。
